This study was undertaken to investigate the treatment schedules used clini
cally for highly proliferative tumours, particularly with reference to the
effects of fraction size, fraction number and treatment duration. The linea
r quadratic model (with time component) is used here to compare non-standar
d treatment regimens (e.g. accelerated and hyperfractionated schedules), cu
rrently the focus of randomized trials, with each other and some common 'st
andard regimens'. To ensure easy interpretation of results, two parameters
known as proliferative standard effective dose one (PSED1) and proliferativ
e standard effective dose two (PSED2) have been calculated for each regimen
.
Graphs of PSED1 and PSED2 versus potential doubling time (T-p) have been ge
nerated for a range of fractionation regimens which are currently under tri
al in various randomized studies. From these graphs it can be seen that the
highly accelerated schedules (such as CHART) only show advantages for tumo
urs with very short potential doubling times. Calculations for most of the
schedules considered showed at least equivalent tumour control expected for
the trial schedule compared with the control arm used and these values agr
ee quite well with clinical results.
These calculations are in good agreement with clinical results available at
present. The greater the PSED1 or PSED2 for the schedule considered the gr
eater the tumour control, which can be expected. However, as has been seen
with clinical trials, this higher cell kill also results in higher acute ef
fects which have proved too great for some accelerated schedules to continu
e.